HC Wainwright Has Negative Estimate for OCUL Q3 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Equities researchers at HC Wainwright reduced their Q3 2026 EPS estimates for Ocular Therapeutix in a research report issued on Tuesday, August 4th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings of ($0.37) per share for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s FY2026 earnings at ($1.49) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.54) EPS.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Friday, July 17th. Robert W. Baird increased their price objective on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Royal Bank Of Canada restated an “outperform” rating and set a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Chardan Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a report on Tuesday. Finally, Zacks Research downgraded shares of Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.75.

Ocular Therapeutix Stock Down 1.0%

Shares of NASDAQ OCUL opened at $8.50 on Thursday. The stock has a market cap of $1.87 billion, a PE ratio of -5.99 and a beta of 0.93. The company has a quick ratio of 14.73, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. Ocular Therapeutix has a 52-week low of $6.23 and a 52-week high of $16.44. The business has a 50-day moving average price of $9.16 and a 200 day moving average price of $9.13.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.The company had revenue of $13.47 million for the quarter, compared to analyst estimates of $13.20 million. During the same quarter last year, the company posted ($0.39) earnings per share. The business’s quarterly revenue was down .1% compared to the same quarter last year.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider owned 2,597,170 shares in the company, valued at approximately $21,296,794. The trade was a 0.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 28,999 shares of company stock valued at $237,792. 3.10% of the stock is currently owned by insiders.

Institutional Trading of Ocular Therapeutix

Several hedge funds have recently modified their holdings of OCUL. Summer Road LLC raised its position in Ocular Therapeutix by 6.9% in the first quarter. Summer Road LLC now owns 11,879,825 shares of the biopharmaceutical company’s stock worth $100,622,000 after acquiring an additional 771,270 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Ocular Therapeutix by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after purchasing an additional 2,411,953 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Ocular Therapeutix by 5.1% during the 4th quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company’s stock worth $130,842,000 after purchasing an additional 527,777 shares during the period. TCG Crossover Management LLC grew its stake in shares of Ocular Therapeutix by 15.0% during the 3rd quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company’s stock worth $71,510,000 after purchasing an additional 798,084 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its stake in shares of Ocular Therapeutix by 15.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company’s stock worth $56,148,000 after purchasing an additional 620,700 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.